Times Square, New York
New York – Every now and then you go to a cancer conference and instead of hearing the expected standard talk that is repeated time and time again for a season or so, you are delighted with a more engaging and uninhibited approach that captivates and informs on the latest state of the art progress.
It also means that more than the presenter realises is perhaps shared. That’s very good news indeed for intrepid science writers and anyone who cares to listen or read.
The research mentioned in today’s post falls in the engaged and delighted category…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Neon Therapeutics is based in Cambridge, MA
One of the much anticipated cancer immunotherapy presentations at the 2017 JP Morgan Healthcare conference was by Neon Therapeutics CEO Hugh O’Dowd.
As readers know we’re riding the Immuno-Oncology wave on Biotech Strategy Blog, and one of the exciting new topics to emerge is whether we can target neoantigens to create personalized immunotherapy.
Our mini-series last year on neonatigens received a lot of attention. It included a primer and three interviews. We were very much of the opinion that Neon Therapeutics is a company to watch out for.
In case you missed them, here are the links:
I highly recommending reading these articles as background on the science and new product development as a prelude to the latest commercialisation update we will cover in today’s post.
What did we learn from the 2017 JP Morgan presentation of the Neon Therapeutics corporate strategy?
If you didn’t make it to the presentation at JPM17 in San Francisco (it wasn’t webcast), you may be interested in this post. This is the latest update in our on-going series on neoantigens and why they matter in cancer immunotherapy.
Subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.